235. Hypoparathyroidism Clinical trials / Disease details

Clinical trials : 88 /  Drugs : 128 - (DrugBank : 25) / Drug target genes : 5 - Drug target pathways : 7

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04701203
(ClinicalTrials.gov)		February 16, 20216/1/2021A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With HypoparathyroidismPaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismHypoparathyroidism;Endocrine System Diseases;Parathyroid DiseasesCombination Product: TransCon PTH;Combination Product: PlaceboAscendis Pharma Bone Diseases A/SNULLActive, not recruiting18 YearsN/AAll82Phase 3United States;Canada;Denmark;Germany;Hungary;Italy;Norway
2NCT04009291
(ClinicalTrials.gov)		August 27, 201920/6/2019A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismPaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismHypoparathyroidism;Endocrine System Diseases;Parathyroid DiseasesCombination Product: TransCon PTH;Combination Product: Placebo for TransCon PTHAscendis Pharma A/SNULLActive, not recruiting18 YearsN/AAll40Phase 2United States;Canada;Denmark;Germany;Italy;Norway;United Kingdom